BRAF and melanoma: Known small-molecule inhibitors of DPEP1 (cilastatin and the LSALT peptide) may exert anti-CM effects, though no relevant studies have been reported to date.[27,35] Additionally, analogous to enfortumab vedotin targeting Nectin4, anti-DPEP1 monoclonal antibodies for tumor-specific payload delivery may achieve targeted cytotoxicity against DPEP1-high melanoma cells, minimizing off-target effects.[36] Combining DPEP1 inhibitors with BRAF/MEK inhibitors may also reduce drug resistance.[37,38] These strategies hold promise for novel precision therapies in CM.